ATE348164T1 - Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie - Google Patents
Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilieInfo
- Publication number
- ATE348164T1 ATE348164T1 AT00935043T AT00935043T ATE348164T1 AT E348164 T1 ATE348164 T1 AT E348164T1 AT 00935043 T AT00935043 T AT 00935043T AT 00935043 T AT00935043 T AT 00935043T AT E348164 T1 ATE348164 T1 AT E348164T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- nucleic acids
- tgf
- vector
- gdf
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 3
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 230000000508 neurotrophic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Eye Examination Apparatus (AREA)
- Developing Agents For Electrophotography (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109714 | 1999-05-17 | ||
| EP99114853 | 1999-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE348164T1 true ATE348164T1 (de) | 2007-01-15 |
Family
ID=26153004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00935043T ATE348164T1 (de) | 1999-05-17 | 2000-05-16 | Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060148709A1 (de) |
| EP (1) | EP1179067B1 (de) |
| JP (1) | JP2002543841A (de) |
| AT (1) | ATE348164T1 (de) |
| AU (1) | AU5067100A (de) |
| CA (1) | CA2372119A1 (de) |
| CY (1) | CY1105910T1 (de) |
| DE (1) | DE60032355T2 (de) |
| DK (1) | DK1179067T3 (de) |
| ES (1) | ES2275513T3 (de) |
| PT (1) | PT1179067E (de) |
| WO (1) | WO2000070051A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914554B1 (de) * | 2000-04-20 | 2010-06-09 | St Vincent's Hospital Sydney Limited | Diagnostischer Assay mit makrophagenhemmendem Zytokin-1 (MIC-1) |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| WO2008015254A2 (en) | 2006-08-04 | 2008-02-07 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| EP1884777A1 (de) * | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Mittel und Verfahren zur Risikobewertung von Herzeingriffen auf GDF-15-Basis |
| CN100588717C (zh) * | 2007-03-21 | 2010-02-10 | 中国医学科学院阜外心血管病医院 | 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途 |
| JP2011501112A (ja) | 2007-10-10 | 2011-01-06 | エフ．ホフマン−ラ ロシュ アーゲー | 心筋梗塞のモニタリング及びその治療のための手段及び方法 |
| EP2103943A1 (de) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern |
| JP5444363B2 (ja) | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
| KR20100054711A (ko) * | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
| EP2211182A1 (de) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Verfahren zur Bewertung des Schweregrades einer Leberzirrhose |
| EP2209003A1 (de) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Mittel und Verfahren zur Differenzierung zwischen Fibrose und Zirrhose |
| BR112012006105A2 (pt) | 2009-09-17 | 2016-06-07 | Hoffmann La Roche | painel de múltiplos marcadores de hipertrofia ventricular esquerda. |
| ES2647461T3 (es) | 2009-12-18 | 2017-12-21 | F. Hoffmann-La Roche Ag | GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca |
| WO2011102461A1 (ja) * | 2010-02-22 | 2011-08-25 | 公立大学法人横浜市立大学 | 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用 |
| EP2388594A1 (de) | 2010-05-17 | 2011-11-23 | Roche Diagnostics GmbH | Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung |
| WO2012020045A1 (en) | 2010-08-10 | 2012-02-16 | Roche Diagnostics Gmbh | Method for selecting patients with stable coronary artery disease for pci or medical treatment |
| EP2609427B1 (de) | 2010-08-26 | 2015-01-21 | Roche Diagnostics GmbH | Verwendung von Biomarkern bei der Beurteilung des frühen Übergangs von arteriellem Bluthochdruck zu Herzinsuffizienz |
| EP2439535A1 (de) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2 |
| WO2012066140A1 (en) | 2010-11-19 | 2012-05-24 | Roche Diagnostics Gmbh | Method for monitoring physical training in healthy and diseased individuals |
| EP2490027A1 (de) | 2011-02-15 | 2012-08-22 | Roche Diagnostics GmbH | Mittel und Verfahren zur Diagnose von Schwangerschaftskomplikationen auf Grundlage von GDF-15 und PlGF/sFlt1 |
| WO2012146645A1 (en) | 2011-04-27 | 2012-11-01 | Roche Diagnostics Gmbh | Diagnosis of kidney injury after surgery |
| EP2574932A1 (de) | 2011-09-30 | 2013-04-03 | Roche Diagnostics GmbH | sFlt1 in Patienten während oder unmittelbar nach körperlicher Betätigung |
| EP2581040A1 (de) | 2011-10-10 | 2013-04-17 | Roche Diagnostics GmbH | TNT-basiertes Herzhypertrophierisiko im Zusammenhang mit physiologischem Training und Führung in Athleten |
| CN105785053B (zh) | 2011-10-17 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 风险患者和中风原因的基于肌钙蛋白和bnp的诊断 |
| US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| EP2597467A1 (de) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Mittel und Verfahren zur proSP-B-basierten Diagnose von Lungenstauung bei Patienten mit akutem Koronarsyndrom |
| PT2900263T (pt) | 2012-09-26 | 2019-07-29 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15) |
| CN113759128A (zh) | 2012-12-04 | 2021-12-07 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EP2950807B1 (de) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Zusammensetzungen und verfahren zur verwendung bei der behandlung von stoffwechselerkrankungen |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2843414B1 (de) | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker zur statinbehandlungsstratifikation bei herzversagen |
| AU2014343709B2 (en) | 2013-11-04 | 2020-11-19 | The Regents Of The University Of Michigan | Biomarkers and methods for progression prediction for chronic kidney disease |
| ES2712201T3 (es) | 2014-01-28 | 2019-05-09 | Hoffmann La Roche | Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B |
| EP3413052B1 (de) | 2014-03-26 | 2022-12-28 | Roche Diagnostics GmbH | Igfbp7 zur diagnose von diastolischer dysfunktion |
| EP3122775B1 (de) | 2014-03-26 | 2019-11-13 | Julius-Maximilians-Universität Würzburg | Monoklonale antikörper gegen wachstums- und differenzierungsfaktor 15 (gdf-15) und verwendungen davon zur behandlung von krebsbedingter kachexie und krebs |
| TN2016000578A1 (en) | 2014-07-30 | 2018-04-04 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| BR112017005554A2 (en) | 2014-10-29 | 2018-01-23 | F. Hoffmann-La Roche Ag | methods for predicting a subject's risk of rapid progression to chronic heart failure and uses of at least one biomarker and at least one binding agent |
| EP3212226B1 (de) | 2014-10-31 | 2020-03-18 | NGM Biopharmaceuticals, Inc. | Zusammensetzungen und verfahren zur verwendung zur behandlung von stoffwechselerkrankungen |
| JP6858181B2 (ja) | 2015-10-02 | 2021-04-14 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ |
| JP6925326B2 (ja) | 2015-10-02 | 2021-08-25 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 |
| ES2774967T3 (es) | 2015-10-08 | 2020-07-23 | Hoffmann La Roche | IGFBP7 para la predicción del riesgo de LRA cuando se mide antes de una intervención quirúrgica |
| CN105603093A (zh) * | 2016-02-05 | 2016-05-25 | 广州复能基因有限公司 | 以MIC-1 cDNA为模板制备RNA探针的方法 |
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| JP2021014434A (ja) * | 2019-07-12 | 2021-02-12 | 国立大学法人千葉大学 | うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１ |
| EP3943946A1 (de) | 2020-07-20 | 2022-01-26 | F. Hoffmann-La Roche AG | Gdf-15 zur vorhersage der erkrankungsschwere eines patienten mit covid-19 |
| IL302646A (en) | 2020-11-10 | 2023-07-01 | Catalym Gmbh | Anti-GDF15 antibody and dosage regimen for cancer treatment |
| WO2022229442A2 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Presepsin marker panels for early detection of sepsis |
| WO2022229415A2 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Gdf15 marker panels for early detection of sepsis |
| US20250035629A1 (en) | 2021-09-29 | 2025-01-30 | Roche Diagnostics Operations, Inc. | Mr-proadm marker panels for early detection of sepsis |
| EP4483186A1 (de) | 2022-02-21 | 2025-01-01 | F. Hoffmann-La Roche AG | Dll1-markertafeln für den frühen nachweis von sepsis |
| CN118922721A (zh) | 2022-03-18 | 2024-11-08 | 豪夫迈·罗氏有限公司 | 用于2型与1型急性心肌梗死的早期辨别的cMyBPC标志物组合 |
| WO2023175152A1 (en) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
| CN114891086B (zh) * | 2022-06-01 | 2024-03-26 | 恺佧生物科技(上海)有限公司 | 一种生物素标记的gdf15的复性方法 |
| WO2024160752A1 (en) | 2023-01-30 | 2024-08-08 | F. Hoffmann-La Roche Ag | Effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180602B1 (en) * | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| US5994102A (en) * | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| EP0833912B1 (de) * | 1995-06-22 | 2009-02-25 | St Vincent's Hospital Sydney Limited | Neues tgf-beta-ahnliches cytokin |
| US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US6524802B1 (en) * | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| WO1998011224A1 (en) * | 1996-09-11 | 1998-03-19 | Ortho-Mcneil Pharmaceutical,Inc | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods |
| FR2761258B1 (fr) * | 1997-03-26 | 1999-06-11 | Rhone Poulenc Rorer Sa | Procede de stimulation de la regeneration nerveuse |
| CA2301693A1 (en) * | 1997-09-19 | 1999-04-01 | Klaus Unsicker | Cytokines having neurotrophic activity |
| DE60035192T2 (de) * | 1999-04-26 | 2008-02-14 | Applied Protein Sciences, LLC, Mountain View | Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung |
-
2000
- 2000-05-16 AT AT00935043T patent/ATE348164T1/de not_active IP Right Cessation
- 2000-05-16 AU AU50671/00A patent/AU5067100A/en not_active Abandoned
- 2000-05-16 EP EP00935043A patent/EP1179067B1/de not_active Expired - Lifetime
- 2000-05-16 CA CA002372119A patent/CA2372119A1/en not_active Abandoned
- 2000-05-16 PT PT00935043T patent/PT1179067E/pt unknown
- 2000-05-16 DE DE60032355T patent/DE60032355T2/de not_active Expired - Fee Related
- 2000-05-16 DK DK00935043T patent/DK1179067T3/da active
- 2000-05-16 ES ES00935043T patent/ES2275513T3/es not_active Expired - Lifetime
- 2000-05-16 JP JP2000618457A patent/JP2002543841A/ja active Pending
- 2000-05-16 WO PCT/EP2000/004445 patent/WO2000070051A1/en not_active Ceased
-
2006
- 2006-03-09 US US11/372,281 patent/US20060148709A1/en not_active Abandoned
-
2007
- 2007-01-08 CY CY20071100023T patent/CY1105910T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1179067A1 (de) | 2002-02-13 |
| PT1179067E (pt) | 2007-01-31 |
| DK1179067T3 (da) | 2007-03-19 |
| EP1179067B1 (de) | 2006-12-13 |
| CA2372119A1 (en) | 2000-11-23 |
| ES2275513T3 (es) | 2007-06-16 |
| DE60032355D1 (de) | 2007-01-25 |
| DE60032355T2 (de) | 2007-04-26 |
| AU5067100A (en) | 2000-12-05 |
| US20060148709A1 (en) | 2006-07-06 |
| CY1105910T1 (el) | 2011-02-02 |
| WO2000070051A1 (en) | 2000-11-23 |
| JP2002543841A (ja) | 2002-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60032355D1 (de) | Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie | |
| ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
| DE69435038D1 (de) | Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie | |
| NO20011386D0 (no) | Nye metoder for fremvisning av (poly)peptider/proteiner pÕ bakteriofage partikler via disulfidbindinger | |
| EP1067182A3 (de) | Sekretorische- oder Membranproteine | |
| IL140287A (en) | Methods for rapidly identifying small organic ligands | |
| ATE180261T1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
| DE60140773D1 (de) | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) | |
| WO2002002627A3 (en) | Interferon-like protein zcyto21 | |
| ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
| BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
| DE69618614D1 (de) | NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG | |
| FR2660757B1 (fr) | Procede d'identification ou de dosage de proteines et applications. | |
| IL162568A0 (en) | fluorescent protein from aequorea coerulscens and uses thereof | |
| WO2002074956A3 (en) | Dopaminergic neuronal survival-promoting factors and uses thereof | |
| WO2004094651A3 (en) | Novel human polypeptides encoded by polynucleotides | |
| WO2001029220A3 (en) | Mage-a12 antigenic peptides and uses thereof | |
| WO2003027251A3 (en) | Novel molecules of the pyrin domain protein family and uses thereof | |
| EP1702985A3 (de) | Bevorzugte neurofilamentprotein Segmente und Methode zu ihrer Verwendung | |
| ATE550345T1 (de) | Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren | |
| ATE187202T1 (de) | Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung | |
| WO2004090103A8 (en) | Identification of novel nogo-receptors and methods related thereto | |
| WO2003042374A3 (de) | Isolierung von neuronen und stammzellen für nervenfasern aus einer probe | |
| DE69937453D1 (de) | Verfahren zur isolierung und charakterisierung potentieller funktionen ausgehend von einer biologischen probe, welche nukleinsäuren enthält | |
| DE60308176D1 (de) | Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1179067 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |